The influence of rosuvastatin on the gastrointestinal microbiota and host gene expression profiles

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 312, Issue 5, 2017, Pages G488-G497

  Nolan, J A ^a,b   Skuse, P ^c   Govindarajan, K ^a,b   Patterson, E ^a,b,c   Konstantinidou, N ^b   Casey, P G ^a   MacSharry, J ^a,b,d   Shanahan, F ^a   Stanton, C ^a,c   Hill, C ^a,b   Cotter, P D ^a,c   Joyce, S A ^a,b,d   Gahan, C G M ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c TEAGASC FOOD RESEARCH CENTRE   (Ireland)

^d UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Bile acid; Inflammation; Isoprenoid; Microbiota; Statin

Indexed keywords

BILE ACID; CHOLESTEROL; CYCLIC AMP; DEFENSIN; DRINKING WATER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; ITGAL PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MUCIN; NITRIC OXIDE SYNTHASE; PROTEIN; REGIII GAMMA PROTEIN; RNA 16S; ROSUVASTATIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE; HYPOCHOLESTEROLEMIC AGENT; IMMUNOLOGIC FACTOR;

ADULT; ANIMAL TISSUE; ARTICLE; BACTEROIDETES; BILE ACID METABOLISM; BILOPHILA; CECUM; CHOLESTEROL BLOOD LEVEL; COMMUNITY STRUCTURE; CONTROLLED STUDY; CORIOBACTERIACEAE; DESULFOVIBRIONACEAE; ENZYME ACTIVITY; ERYSIPELOTRICHACEAE; FECES; FEMALE; FIRMICUTES; GENE EXPRESSION; INTESTINE FLORA; LIVER TISSUE; MICROBIAL COMMUNITY; MOLLICUTES; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOBACTERIA; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECIES RICHNESS; VERRUCOMICROBIA; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECTS; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED C57BL; ROSUVASTATIN CALCIUM;

EID: 85018414497     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00149.2016     Document Type: Article

References (63)

1. Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev 29: 625–651, 2005. doi:10.1016/j.femsre.2004.09.003.
2. Bergström A, Kristensen MB, Bahl MI, Metzdorff SB, Fink LN, Frøkiaer H, Licht TR. Nature of bacterial colonization influences transcription of mucin genes in mice during the first week of life. BMC Res Notes 5: 402, 2012. doi:10.1186/1756-0500-5-402.
3. Bubeck Wardenburg J, Patel RJ, Schneewind O. Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect Immun 75: 1040–1044, 2007. doi:10.1128/IAI.01313-06.
4. Cani PD, Everard A. [Akkermansia muciniphila: a novel target controlling obesity, type 2 diabetes and inflammation?]. Med Sci (Paris) 30: 125–127, 2014. doi:10.1051/medsci/20143002003.
5. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7: 335–336, 2010. doi:10.1038/nmeth.f.303.
6. Catry E, Pachikian BD, Salazar N, Neyrinck AM, Cani PD, Delzenne NM. Ezetimibe and simvastatin modulate gut microbiota and expression of genes related to cholesterol metabolism. Life Sci 132: 77–84, 2015. doi:10.1016/j.lfs.2015.04.004.
7. Chen VB, Davis IW, Richardson DC. KING (Kinemage, Next Generation): a versatile interactive molecular and scientific visualization program. Protein Sci 18: 2403–2409, 2009. doi:10.1002/pro.250.
8. Chiang KH, Cheng WL, Shih CM, Lin YW, Tsao NW, Kao YT, Lin CT, Wu SC, Huang CY, Lin FY. Statins, HMG-CoA reductase inhibitors, improve neovascularization by increasing the expression density of CXCR4 in endothelial progenitor Cells. PLoS One 10: e0136405, 2015. doi:10.1371/journal.pone.0136405.
9. Chow OA, von Köckritz-Blickwede M, Bright AT, Hensler ME, Zinkernagel AS, Cogen AL, Gallo RL, Monestier M, Wang Y, Glass CK, Nizet V. Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe 8: 445–454, 2010. doi:10.1016/j.chom.2010.10.005.
10. Claesson MJ, Wang Q, O’Sullivan O, Greene-Diniz R, Cole JR, Ross RP, O’Toole PW. Comparison of two next-generation sequencing technologies for resolving highly complex microbiota composition using tandem variable 16S rRNA gene regions. Nucleic Acids Res 38: e200, 2010. doi:10.1093/nar/gkq873.
11. Clarke SF, Murphy EF, Nilaweera K, Ross PR, Shanahan F, O’Toole PW, Cotter PD. The gut microbiota and its relationship to diet and obesity: new insights. Gut Microbes 3: 186–202, 2012. doi:10.4161/gmic.20168.
12. Davey KJ, Cotter PD, O’Sullivan O, Crispie F, Dinan TG, Cryan JF, O’Mahony SM. Antipsychotics and the gut microbiome: olanzapineinduced metabolic dysfunction is attenuated by antibiotic administration in the rat. Transl Psychiatry 3: e309, 2013. doi:10.1038/tp.2013.83.
13. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, Antonopoulos DA, Jabri B, Chang EB. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 487: 104–108, 2012. doi:10.1038/nature11225.
14. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 110: 9066–9071, 2013. doi:10.1073/pnas.1219451110.
15. Fouhy F, Guinane CM, Hussey S, Wall R, Ryan CA, Dempsey EM, Murphy B, Ross RP, Fitzgerald GF, Stanton C, Cotter PD. Highthroughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. Antimicrob Agents Chemother 56: 5811–5820, 2012. doi:10.1128/AAC.00789-12.
16. Haas BJ, Gevers D, Earl AM, Feldgarden M, Ward DV, Giannoukos G, Ciulla D, Tabbaa D, Highlander SK, Sodergren E, Methé B, DeSantis TZ, Petrosino JF, Knight R, Birren BW; Human Microbiome Consortium. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res 21: 494–504, 2011. doi:10.1101/gr.112730.110.
17. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27: 104–119, 2008. doi:10.1111/j.1365-2036.2007.03562.x.
18. Hennessy E, Mooij MJ, Legendre C, Reen FJ, O’Callaghan J, Adams C, O’Gara F. Statins inhibit in vitro virulence phenotypes of Pseudomonas aeruginosa. J Antibiot (Tokyo) 66: 99–101, 2013. doi:10.1038/ja.2012.95.
19. Heuston S, Begley M, Gahan CG, Hill C. Isoprenoid biosynthesis in bacterial pathogens. Microbiology 158: 1389–1401, 2012. doi:10.1099/mic.0.051599-0.
20. Huson DH, Richter DC, Rausch C, Dezulian T, Franz M, Rupp R. Dendroscope: an interactive viewer for large phylogenetic trees. BMC Bioinformatics 8: 460, 2007. doi:10.1186/1471-2105-8-460.
21. Islam KB, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, Ogura Y, Hayashi T, Yokota A. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 141: 1773–1781, 2011. doi:10.1053/j.gastro.2011.07.046.
22. Istvan ES. Structural mechanism for statin inhibition of 3-hydroxy-3- methylglutaryl coenzyme A reductase. Am Heart J 144, Suppl: S27–S32, 2002. doi:10.1067/mhj.2002.130300.
23. Iusuf D, van Esch A, Hobbs M, Taylor M, Kenworthy KE, van de Steeg E, Wagenaar E, Schinkel AH. Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure. Mol Pharmacol 83: 919–929, 2013. doi:10.1124/mol.112.081927.
24. Jäger S, Stange EF, Wehkamp J. Antimicrobial peptides in gastrointestinal inflammation. Int J Inflamm 2010: 910283, 2010. doi:10.4061/2010/910283.
25. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 61: 362–364, 2008. doi:10.1093/jac/dkm496.
26. Johansen ME, Green LA, Sen A, Kircher S, Richardson CR. Cardiovascular risk and statin use in the United States. Ann Fam Med 12: 215–223, 2014. doi:10.1370/afm.1641.
27. Joyce SA, Gahan CG. The gut microbiota and the metabolic health of the host. Curr Opin Gastroenterol 30: 120–127, 2014. doi:10.1097/MOG.0000000000000039.
28. Joyce SA, MacSharry J, Casey PG, Kinsella M, Murphy EF, Shanahan F, Hill C, Gahan CG. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci USA 111: 7421–7426, 2014. doi:10.1073/pnas.1323599111.
29. Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng ZB, Wiest MM, Nguyen UT, Wojnoonski K, Watkins SM, Trupp M, Krauss RM. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One 6: e25482, 2011. doi:10.1371/journal.pone.0025482.
30. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89–118, 2005. doi:10.1146/annurev.pharmtox.45.120403.095748.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta C(T)) method. Methods 25: 402–408, 2001. doi:10.1006/meth.2001.1262.
32. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 294: 1–8, 2009. doi:10.1111/j.1574-6968.2009.01514.x.
33. Ma PT, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 83: 8370–8374, 1986. doi:10.1073/pnas.83.21.8370.
34. Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25: 2822–2835, 2003. doi:10.1016/S0149-2918(03)80336-3.
35. Martínez I, Perdicaro DJ, Brown AW, Hammons S, Carden TJ, Carr TP, Eskridge KM, Walter J. Diet-induced alterations of host cholesterol metabolism are likely to affect the gut microbiota composition in hamsters. Appl Environ Microbiol 79: 516–524, 2013. doi:10.1128/AEM.03046-12.
36. Martínez I, Wallace G, Zhang C, Legge R, Benson AK, Carr TP, Moriyama EN, Walter J. Diet-induced metabolic improvements in a hamster model of hypercholesterolemia are strongly linked to alterations of the gut microbiota. Appl Environ Microbiol 75: 4175–4184, 2009. doi:10.1128/AEM.00380-09.
37. Masadeh M, Mhaidat N, Alzoubi K, Al-Azzam S, Alnasser Z. Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin. Ann Clin Microbiol Antimicrob 11: 13, 2012. doi:10.1186/1476-0711-11-13.
38. Maurice CF, Haiser HJ, Turnbaugh PJ. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152: 39–50, 2013. doi:10.1016/j.cell.2012.10.052.
39. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)–can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 97: 33A–41A, 2006. doi:10.1016/j.amjcard.2005.11.014.
40. Motzkus-Feagans CA, Pakyz A, Polk R, Gambassi G, Lapane KL. Statin use and the risk of Clostridium difficile in academic medical centres. Gut 61: 1538–1542, 2012. doi:10.1136/gutjnl-2011-301378.
41. Mukherjee S, Vaishnava S, Hooper LV. Multi-layered regulation of intestinal antimicrobial defense. Cell Mol Life Sci 65: 3019–3027, 2008. doi:10.1007/s00018-008-8182-3.
42. Nenseter MS, Aukrust P, Ose L, Holven KB. Low level of inflammatory marker in hyperhomocysteinemic patients on statin therapy. Scand J Clin Lab Invest 74: 1–7, 2014. doi:10.3109/00365513.2013.854926.
43. Nolan JA, Kinsella M, Hill C, Joyce SA, Gahan CG. Analysis of the impact of rosuvastatin on bacterial mevalonate production using a UPLCmass spectrometry approach. Curr Microbiol 73: 1–8, 2016. doi:10.1007/s00284-016-1014-z.
44. Noto D, Cefalù AB, Averna MR. Beyond statins: new lipid lowering strategies to reduce cardiovascular risk. Curr Atheroscler Rep 16: 414, 2014. doi:10.1007/s11883-014-0414-4.
45. Ortego M, Bustos C, Hernández-Presa MA, Tuñón J, Díaz C, Hernández G, Egido J. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147: 253–261, 1999. doi:10.1016/S0021-9150(99)00193-8.
46. Ostaff MJ, Stange EF, Wehkamp J. Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med 5: 1465–1483, 2013. doi:10.1002/emmm.201201773.
47. Patterson AD, Turnbaugh PJ. Microbial determinants of biochemical individuality and their impact on toxicology and pharmacology. Cell Metab 20: 761–768, 2014. doi:10.1016/j.cmet.2014.07.002.
48. Patterson E, O’Doherty RM, Murphy EF, Wall R, O’Sullivan OS, Nilaweera K, Fitzgerald GF, Cotter PD, Ross RP, Stanton C. Impact of dietary fatty acids on metabolic activity and host intestinal microbiota composition in C57BL/6J mice. Br J Nutr 111: 1–13, 2014. doi:10.1017/S0007114514000117.
49. Pitman WA, Osgood DP, Smith D, Schaefer EJ, Ordovas JM. The effects of diet and lovastatin on regression of fatty streak lesions and on hepatic and intestinal mRNA levels for the LDL receptor and HMG CoA reductase in F1B hamsters. Atherosclerosis 138: 43–52, 1998. doi:10.1016/S0021-9150(97)00302-X.
50. Price MN, Dehal PS, Arkin AP. FastTree 2–approximately maximumlikelihood trees for large alignments. PLoS One 5: e9490, 2010. doi:10.1371/journal.pone.0009490.
51. Qiao Y, Sun J, Ding Y, Le G, Shi Y. Alterations of the gut microbiota in high-fat diet mice is strongly linked to oxidative stress. Appl Microbiol Biotechnol 97: 1689–1697, 2013. doi:10.1007/s00253-012-4323-6.
52. Rea MC, Dobson A, O’Sullivan O, Crispie F, Fouhy F, Cotter PD, Shanahan F, Kiely B, Hill C, Ross RP. Effect of broad- and narrowspectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci USA 108, Suppl 1: 4639–4644, 2011. doi:10.1073/pnas.1001224107.
53. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353: 983–984, 1999. doi:10.1016/S0140-6736(98)05917-0.
54. Sommer F, Adam N, Johansson ME, Xia L, Hansson GC, Bäckhed F. Altered mucus glycosylation in core 1 O-glycan-deficient mice affects microbiota composition and intestinal architecture. PLoS One 9: e85254, 2014. doi:10.1371/journal.pone.0085254.
55. Song X, Liu BC, Lu XY, Yang LL, Zhai YJ, Eaton AF, Thai TL, Eaton DC, Ma HP, Shen BZ. Lovastatin inhibits human B lymphoma cell proliferation by reducing intracellular ROS and TRPC6 expression. Biochim Biophys Acta 1843: 894–901, 2014. doi:10.1016/j.bbamcr.2014.02.002.
56. Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, Nicholson JK, Holmes E. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci USA 108, Suppl 1: 4523–4530, 2011. doi:10.1073/pnas.1006734107.
57. Thongtang N, Diffenderfer MR, Ooi EM, Asztalos BF, Dolnikowski GG, Lamon-Fava S, Schaefer EJ. Effects of atorvastatin on human C-reactive protein metabolism. Atherosclerosis 226: 466–470, 2013. doi:10.1016/j.atherosclerosis.2012.11.012.
58. Tokuhara K, Habara K, Oishi M, Miki H, Tanaka Y, Kaibori M, Nishizawa M, Okumura T, Kwon AH. Fluvastatin inhibits the induction of inducible nitric oxide synthase, an inflammatory biomarker, in hepatocytes. Hepatol Res 43: 775–784, 2013. doi:10.1111/hepr.12017.
59. Urich T, Lanzén A, Qi J, Huson DH, Schleper C, Schuster SC. Simultaneous assessment of soil microbial community structure and function through analysis of the meta-transcriptome. PLoS One 3: e2527, 2008. doi:10.1371/journal.pone.0002527.
60. Vaishnava S, Yamamoto M, Severson KM, Ruhn KA, Yu X, Koren O, Ley R, Wakeland EK, Hooper LV. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science 334: 255–258, 2011. doi:10.1126/science.1209791.
61. Wall R, Marques TM, O’Sullivan O, Ross RP, Shanahan F, Quigley EM, Dinan TG, Kiely B, Fitzgerald GF, Cotter PD, Fouhy F, Stanton C. Contrasting effects of Bifidobacterium breve NCIMB 702258 and Bifidobacterium breve DPC 6330 on the composition of murine brain fatty acids and gut microbiota. Am J Clin Nutr 95: 1278–1287, 2012. doi:10.3945/ajcn.111.026435.
62. Wan M, van der Does AM, Tang X, Lindbom L, Agerberth B, Haeggström JZ. Antimicrobial peptide LL-37 promotes bacterial phagocytosis by human macrophages. J Leukoc Biol 95: 971–981, 2014. doi:10.1189/jlb.0513304.
63. Yokota A, Fukiya S, Islam KB, Ooka T, Ogura Y, Hayashi T, Hagio M, Ishizuka S. Is bile acid a determinant of the gut microbiota on a high-fat diet? Gut Microbes 3: 455–459, 2012. doi:10.4161/gmic.21216.